MedTrace Logo

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

NCT06405490 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-12-24

No results posted yet for this study

Summary

This study is a single-center, Phase II Study to assess the efficacy and safety of the regimen of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in combination with Cadonilimab in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.

Conditions

  • Nanoliposomal Irinotecan
  • Cadonilimab
  • Oxaliplatin
  • Capecitabine
  • First-Line
  • Advanced Cancer
  • Pancreatic Adenocarcinoma
  • Drug Use

Interventions

DRUG

Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab

Use the above medications on a regular basis

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-17
Primary Completion
2026-08-30
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06405490 on ClinicalTrials.gov